{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:25:32Z","timestamp":1740108332413,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T00:00:00Z","timestamp":1548028800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00228-019-02627-y","type":"journal-article","created":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T04:41:58Z","timestamp":1548045718000},"page":"717-722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Persistence and treatment-free interval in patients being prescribed biological drugs in rheumatology practices in Germany"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-7227","authenticated-orcid":false,"given":"Karel","family":"Kostev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,21]]},"reference":[{"issue":"Suppl 3","key":"2627_CR1","doi-asserted-by":"publisher","first-page":"S265","DOI":"10.1186\/ar578","volume":"4","author":"AJ Silman","year":"2002","unstructured":"Silman AJ, Pearson JE (2002) Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 4(Suppl 3):S265\u2013S272. \n                    https:\/\/doi.org\/10.1186\/ar578","journal-title":"Arthritis Res"},{"key":"2627_CR2","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","volume":"53","author":"LE Dean","year":"2014","unstructured":"Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ (2014) Global prevalence of ankylosing spondylitis. Rheumatology (Oxford) 53:650\u2013657. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/ket387","journal-title":"Rheumatology (Oxford)"},{"key":"2627_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","volume":"48","author":"L Scotti","year":"2018","unstructured":"Scotti L, Franchi M, Marchesoni A, Corrao G (2018) Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 48:28\u201334. \n                    https:\/\/doi.org\/10.1016\/j.semarthrit.2018.01.003","journal-title":"Semin Arthritis Rheum"},{"key":"2627_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G","volume":"41","author":"J Braun","year":"1998","unstructured":"Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41:58\u201367. \n                    https:\/\/doi.org\/10.1002\/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G","journal-title":"Arthritis Rheum"},{"key":"2627_CR5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00393-016-0088-0","volume":"75","author":"S Hense","year":"2016","unstructured":"Hense S, Luque Ramos A, Callhoff J, Albrecht K, Zink A, Hoffmann F (2016) Prevalence of rheumatoid arthritis in Germany based on health insurance data : regional differences and first results of the PROCLAIR study. Z Rheumatol 75:819\u2013827. \n                    https:\/\/doi.org\/10.1007\/s00393-016-0088-0","journal-title":"Z Rheumatol"},{"key":"2627_CR6","doi-asserted-by":"publisher","first-page":"A566","DOI":"10.1016\/j.jval.2016.09.1268","volume":"19","author":"C Jacob","year":"2016","unstructured":"Jacob C, Meier F, Neidhardt K, Jugl SM, Walker J, Braun S, Augustin M (2016) Epidemiology and costs of psoriatic arthritis in Germany\u2014a retrospective claims data analysis. Value Health 19:A566. \n                    https:\/\/doi.org\/10.1016\/j.jval.2016.09.1268","journal-title":"Value Health"},{"key":"2627_CR7","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/j.1365-2133.2008.09023.x","volume":"160","author":"K Reich","year":"2009","unstructured":"Reich K, Kr\u00fcger K, M\u00f6ssner R, Augustin M (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160:1040\u20131047. \n                    https:\/\/doi.org\/10.1111\/j.1365-2133.2008.09023.x","journal-title":"Br J Dermatol"},{"key":"2627_CR8","unstructured":"Braun J, Kellner H, Max R, Rihl M, Schmitz-Bortz E, Schulze-Koops H, Zinke S, Fan T, Ding Q, Lyu R (2013) Disease severity, quality of life, and productivity loss among patients with ankylosing spondylitis in Germany. In ACR Meeting Abstracts. \n                    https:\/\/acrabstracts.org\/abstract\/disease-severity-quality-of-lifeand-productivity-loss-among-patients-with-ankylosing-spondylitis-in-germany\/"},{"key":"2627_CR9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","volume":"74","author":"J Listing","year":"2015","unstructured":"Listing J, Kekow J, Manger B, Burmester G-R, Pattloch D, Zink A, Strangfeld A (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF\u03b1 inhibitors and rituximab. Ann Rheum Dis 74:415\u2013421. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2013-204021","journal-title":"Ann Rheum Dis"},{"key":"2627_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00393-017-0294-4","volume":"77","author":"K Albrecht","year":"2018","unstructured":"Albrecht K, Luque Ramos A, Callhoff J, Hoffmann F, Minden K, Zink A (2018) Outpatient care and disease burden of rheumatoid arthritis : results of a linkage of claims data and a survey of insured persons. Z Rheumatol 77:102\u2013112. \n                    https:\/\/doi.org\/10.1007\/s00393-017-0294-4","journal-title":"Z Rheumatol"},{"key":"2627_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","volume":"33","author":"JR Curtis","year":"2011","unstructured":"Curtis JR, Singh JA (2011) Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther 33:679\u2013707. \n                    https:\/\/doi.org\/10.1016\/j.clinthera.2011.05.044","journal-title":"Clin Ther"},{"key":"2627_CR12","doi-asserted-by":"publisher","unstructured":"Rosman Z, Shoenfeld Y, Zandman-Goddard G (2013) Biologic therapy for autoimmune diseases: an update. BMC Med 11(88). \n                    https:\/\/doi.org\/10.1186\/1741-7015-11-88","DOI":"10.1186\/1741-7015-11-88"},{"key":"2627_CR13","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960\u2013977. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2016-210715","journal-title":"Ann Rheum Dis"},{"key":"2627_CR14","doi-asserted-by":"publisher","unstructured":"M\u00f3csai A, Kov\u00e1cs L, Gergely P (2014) What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med 12(43). \n                    https:\/\/doi.org\/10.1186\/1741-7015-12-43","DOI":"10.1186\/1741-7015-12-43"},{"key":"2627_CR15","doi-asserted-by":"publisher","first-page":"R52","DOI":"10.1186\/ar2670","volume":"11","author":"AA Saad","year":"2009","unstructured":"Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DPM (2009) British Society for Rheumatology Biologics Register: persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 11:R52. \n                    https:\/\/doi.org\/10.1186\/ar2670","journal-title":"Arthritis Res Ther"},{"key":"2627_CR16","doi-asserted-by":"publisher","first-page":"e105193","DOI":"10.1371\/journal.pone.0105193","volume":"9","author":"A Fisher","year":"2014","unstructured":"Fisher A, Bassett K, Wright JM, Brookhart MA, Freeman H, Dormuth CR (2014) Comparative persistence of the TNF antagonists in rheumatoid arthritis\u2014a population-based cohort study. PLoS One 9:e105193. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0105193","journal-title":"PLoS One"},{"key":"2627_CR17","doi-asserted-by":"publisher","first-page":"A384","DOI":"10.1016\/j.jval.2014.08.2635","volume":"17","author":"M Govoni","year":"2014","unstructured":"Govoni M, Lyu R, Ding Q, Fan T (2014) Persistence rate with subcutaneous biologic therapies in patients with ankylosing spondylitis (As). Value Health 17:A384. \n                    https:\/\/doi.org\/10.1016\/j.jval.2014.08.2635","journal-title":"Value Health"},{"key":"2627_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1590\/S1518-8787.2016050006265","volume":"50","author":"MA \u00c1vila Machado de","year":"2016","unstructured":"de \u00c1vila Machado MA, de Moura CS, Ferr\u00e9 F, Bernatsky S, Rahme E, de Assis Acurcio F (2016) Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis. Rev Saude Publica 50:50. \n                    https:\/\/doi.org\/10.1590\/S1518-8787.2016050006265","journal-title":"Rev Saude Publica"},{"key":"2627_CR19","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2147\/PPA.S110147","volume":"10","author":"J Mahlich","year":"2016","unstructured":"Mahlich J, Sruamsiri R (2016) Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan. Patient Prefer Adherence 10:1509\u20131519. \n                    https:\/\/doi.org\/10.2147\/PPA.S110147","journal-title":"Patient Prefer Adherence"},{"key":"2627_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12891-016-1102-z","volume":"17","author":"JB Palmer","year":"2016","unstructured":"Palmer JB, Li Y, Herrera V, Liao M, Tran M, Ozturk ZE (2016) Treatment patterns and costs for anti-TNF\u03b1 biologic therapy in patients with psoriatic arthritis. BMC Musculoskelet Disord 17:261. \n                    https:\/\/doi.org\/10.1186\/s12891-016-1102-z","journal-title":"BMC Musculoskelet Disord"},{"key":"2627_CR21","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1007\/s12325-017-0617-5","volume":"34","author":"B Chastek","year":"2017","unstructured":"Chastek B, Chen C-I, Proudfoot C, Shinde S, Kuznik A, Wei W (2017) Treatment persistence and healthcare costs among patients with rheumatoid arthritis changing biologics in the USA. Adv Ther 34:2422\u20132435. \n                    https:\/\/doi.org\/10.1007\/s12325-017-0617-5","journal-title":"Adv Ther"},{"key":"2627_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/CEOR.S108730","volume":"9","author":"L Degli Esposti","year":"2017","unstructured":"Degli Esposti L, Favalli EG, Sangiorgi D, Di Turi R, Farina G, Gambera M, Ravasio R (2017) Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy. Clinicoecon Outcomes Res 9:9\u201317. \n                    https:\/\/doi.org\/10.2147\/CEOR.S108730","journal-title":"Clinicoecon Outcomes Res"},{"key":"2627_CR23","doi-asserted-by":"publisher","first-page":"e000596","DOI":"10.1136\/rmdopen-2017-000596","volume":"4","author":"KM Fagerli","year":"2018","unstructured":"Fagerli KM, Kearsley-Fleet L, Watson KD, Packham J, Contributors Group B-R, Symmons DPM, Hyrich KL (2018) Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register. RMD Open 4:e000596. \n                    https:\/\/doi.org\/10.1136\/rmdopen-2017-000596","journal-title":"RMD Open"},{"key":"2627_CR24","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.semarthrit.2017.08.007","volume":"47","author":"M-Y Lee","year":"2018","unstructured":"Lee M-Y, Shin J-Y, Park S-Y, Kim D, Cha H-S, Lee E-K (2018) Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: an analysis of the South Korean National Health Insurance Database. Semin Arthritis Rheum 47:485\u2013491. \n                    https:\/\/doi.org\/10.1016\/j.semarthrit.2017.08.007","journal-title":"Semin Arthritis Rheum"},{"key":"2627_CR25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2217\/cer-2017-0076","volume":"7","author":"JA Walsh","year":"2018","unstructured":"Walsh JA, Adejoro O, Chastek B, Park Y (2018) Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database. J Comp Eff Res 7:369\u2013380. \n                    https:\/\/doi.org\/10.2217\/cer-2017-0076","journal-title":"J Comp Eff Res"},{"key":"2627_CR26","volume-title":"Use of electronic medical records in the epidemiological research","author":"S Dombrowski","year":"2017","unstructured":"Dombrowski S, Kostev K (2017) Use of electronic medical records in the epidemiological research. Cuvillier Verlag, G\u00f6ttingen"},{"key":"2627_CR27","doi-asserted-by":"publisher","first-page":"A635","DOI":"10.1016\/j.jval.2015.09.2252","volume":"18","author":"N Gossen","year":"2015","unstructured":"Gossen N, Kostev K (2015) Reduction in C-reactive protein with biologic drugs in rheumatoid arthritis and spondylitis patients in German rheumatologist practices. Value in Health 18:A635. \n                    https:\/\/doi.org\/10.1016\/j.jval.2015.09.2252","journal-title":"Value in Health"},{"key":"2627_CR28","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00296-016-3448-9","volume":"36","author":"N Gossen","year":"2016","unstructured":"Gossen N, Jacob L, Kostev K (2016) Second-line therapy with biological drugs in rheumatoid arthritis patients in German rheumatologist practices: a retrospective database analysis. Rheumatol Int 36:1113\u20131118. \n                    https:\/\/doi.org\/10.1007\/s00296-016-3448-9","journal-title":"Rheumatol Int"},{"key":"2627_CR29","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11136-016-1387-2","volume":"26","author":"J Drosselmeyer","year":"2017","unstructured":"Drosselmeyer J, Jacob L, Rathmann W, Rapp MA, Kostev K et al (2017) Qual Life Res Int J Qual Life Asp Treat Care Rehab 26:437\u2013443. \n                    https:\/\/doi.org\/10.1007\/s11136-016-1387-2","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehab"},{"key":"2627_CR30","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.amjmed.2005.12.021","volume":"119","author":"DT Gold","year":"2006","unstructured":"Gold DT, McClung B (2006) Approaches to patient education: emphasizing the long-term value of compliance and persistence. Am J Med 119:S32\u2013S37. \n                    https:\/\/doi.org\/10.1016\/j.amjmed.2005.12.021","journal-title":"Am J Med"},{"key":"2627_CR31","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/jnci\/djn124","volume":"100","author":"S Woloshin","year":"2008","unstructured":"Woloshin S, Schwartz LM, Welch HG (2008) The risk of death by age, sex, and smoking status in the United States: putting health risks in context. J Natl Cancer Inst 100:845\u2013853. \n                    https:\/\/doi.org\/10.1093\/jnci\/djn124","journal-title":"J Natl Cancer Inst"},{"key":"2627_CR32","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","volume":"381","author":"A Clegg","year":"2013","unstructured":"Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K (2013) Frailty in elderly people. Lancet 381:752\u2013762. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(12)62167-9","journal-title":"Lancet"},{"key":"2627_CR33","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.3899\/jrheum.160012","volume":"43","author":"A Murota","year":"2016","unstructured":"Murota A, Kaneko Y, Yamaoka K, Takeuchi T (2016) Safety of biologic agents in elderly patients with rheumatoid arthritis. J Rheumatol 43:1984\u20131988. \n                    https:\/\/doi.org\/10.3899\/jrheum.160012","journal-title":"J Rheumatol"},{"key":"2627_CR34","first-page":"29","volume":"36","author":"L Leon","year":"2018","unstructured":"Leon L, Gomez A, Vadillo C, Pato E, Rodriguez-Rodriguez L, Jover JA, Abasolo L (2018) Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice. Clin Exp Rheumatol 36:29\u201335 28598787","journal-title":"Clin Exp Rheumatol"},{"key":"2627_CR35","first-page":"680","volume":"35","author":"S Lee","year":"2010","unstructured":"Lee S, Mendelsohn A, Sarnes E (2010) The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T 35:680\u2013689","journal-title":"P T"},{"key":"2627_CR36","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jjcc.2014.02.018","volume":"64","author":"H Masuda","year":"2014","unstructured":"Masuda H, Miyazaki T, Shimada K, Tamura N, Matsudaira R, Yoshihara T, Ohsaka H, Sai E, Matsumori R, Fukao K, Hiki M, Kume A, Kiyanagi T, Takasaki Y, Daida H (2014) Disease duration and severity impacts on long-term cardiovascular events in Japanese patients with rheumatoid arthritis. J Cardiol 64:366\u2013370. \n                    https:\/\/doi.org\/10.1016\/j.jjcc.2014.02.018","journal-title":"J Cardiol"},{"key":"2627_CR37","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s10067-017-3767-6","volume":"36","author":"F Jamalyaria","year":"2017","unstructured":"Jamalyaria F, Ward MM, Assassi S, Learch TJ, Lee M, Gensler LS, Brown MA, Diekman L, Tahanan A, Rahbar MH, Weisman MH, Reveille JD (2017) Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups. Clin Rheumatol 36:2359\u20132364. \n                    https:\/\/doi.org\/10.1007\/s10067-017-3767-6","journal-title":"Clin Rheumatol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02627-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02627-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02627-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T19:06:10Z","timestamp":1579547170000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02627-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,21]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["2627"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02627-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2019,1,21]]},"assertion":[{"value":"26 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}